Franz-Josef Obermair

Franz-Josef Obermair

Auto-generated profile, based on publicly available information

Franz-Josef Obermair

Repertoire Immune Medicines, Schlieren, Switzerland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2022 in Science Advances
Verified
Journal Article
Open access
FOFranz-Josef Obermair
Franz-Josef Obermair
FRFlorian Renoux
Florian Renoux
SHSebastian Heer
Sebastian Heer
CLChloe H. Lee
Chloe H. Lee
NCNastassja Cereghetti
Nastassja Cereghetti
JKJan Kisielow
Jan Kisielow
Understanding peptide presentation by specific MHC alleles is fundamental for controlling physiological functions of T cells and harnessing them for therapeutic use. However, commonly used in silico predictions and mass spectroscopy have their limitations in precision, sensitivity, and throughput, particularly for MHC class II. Here, we present MEDi, a novel mammalian epitope display that allows an unbiased, affordable, high-resolution mapping of MHC peptide presentation capacity. Our platform provides a detailed picture by testing every antigen-derived peptide and is scalable to all the MHC II alleles. Given the urgent need to understand immune evasion for formulating effective responses to threats such as SARS-CoV-2, we provide a comprehensive analysis of the presentability of all SARS-CoV-2 peptides in the context of several HLA class II alleles. We show that several mutations arising in viral strains expanding globally resulted in reduced peptide presentability by multiple HLA class II alleles, while some increased it, suggesting alteration of MHC II presentation landscapes as a possible immune escape mechanism.

28 November 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
BLBenjamin Y. Lu
Benjamin Y. Lu
LLLiliana E. Lucca
Liliana E. Lucca
WLWesley Lewis
Wesley Lewis
JWJiping Wang
Jiping Wang
CNCatarina V. Nogueira
Catarina V. Nogueira
DHDavid A. Hafler
David A. Hafler

28 February 2024 in Research Square
Verified
Preprint
Open access
PDF file
DHDavid Hafler
David Hafler
BLBenjamin Lu
Benjamin Lu
LLLiliana Lucca
Liliana Lucca
WLWesley Lewis
Wesley Lewis
JWJiping Wang
Jiping Wang
HKHarriet Kluger
Harriet Kluger
Effective anti-tumor immunity is largely driven by cytotoxic CD8+ T cells that can specifically recognize tumor antigens. However, the factors which ultimately dictate successful tumor rejection remain poorly understood. Here we identify a subpopulation of CD8+ T cells which are tumor antigen-specific in patients with melanoma but resemble KIR+CD8+ T cells with a regulatory function (Tregs). These tumor antigen-specific KIR+CD8+ T cells are detectable in both the tumor and the blood, and higher levels of this population are associated with worse overall survival. Our findings therefore suggest that KIR+CD8+ Tregs are tumor antigen-specific but uniquely suppress anti-tumor immunity in patients with melanoma.